TNF and medulloblastoma: Thus, our RGD4C.TPA.TNFα particle provides selective and efficient systemic delivery of TNFα to medulloblastoma, yielding a potential TNFα anti‐medulloblastoma therapy while sparing healthy tissues from the systemic toxicity of this cytokine.